From the Blood Journals

From the Blood Journals

Research from the Blood family of journals: Blood and Blood Advances

WIB_icon

A Pediatric Regimen Is Effective for Adolescents and Young Adults With ALL

Adolescents and young adults (AYAs) with newly diagnosed acute lymphocytic leukemia (ALL) who received a pediatric-inspired regimen had better survival outcomes than historical controls,...
WIB_icon

Study Identifies Genetic Markers That Predict Radiation-Induced Breast Cancer After Hodgkin Lymphoma

The risk of developing breast cancer is high in women with Hodgkin lymphoma (HL) who have undergone chest radiotherapy (RT), but the role of...
WIB_icon

Azacitidine Maintenance Improves Disease-Free Survival in Older Patients with Newly Diagnosed AML

Older patients with acute myeloid leukemia (AML) in complete remission (CR) who received maintenance therapy with subcutaneous azacitidine had longer disease-free survival (DFS), compared...
WIB_icon

Enasidenib Induces Molecular Remissions in IDH2-Mutated, Relapsed/Refractory AML

A first-in-human trial of patients with relapsed and/or refractory, IDH2-mutated acute myeloid leukemia (AML) found that the IDH2 inhibitor enasidenib was an effective salvage...
WIB_icon

Ravulizumab: A New Complement Inhibitor for Patients With Paroxysmal Nocturnal Hemoglobinuria

Ravulizumab was noninferior to eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) who had never received treatment with complement inhibitors, according to findings from...
WIB_icon

Can a Selinexor Combination STOMP Out Relapsed/Refractory Multiple Myeloma?

The combination of selinexor plus low-dose bortezomib and dexamethasone produced high response rates in patients with relapsed or refractory multiple myeloma (MM), with a...
WIB_icon

Duvelisib Bests Ofatumumab in Relapsed and Refractory CLL/SLL

In the phase III DUO trial, treatment with the oral phosphoinositide 3-kinase (PI3K) dual inhibitor duvelisib improved progression-free survival (PFS) and overall response, compared...

Weighing Conditioning Regimens for Patients With CML Undergoing Transplant

Conditioning with a reduced-intensity, nonmyeloablative regimen was associated with similar post-transplant survival but a lower risk of chronic graft-versus-host disease (cGVHD), compared with a...
WIB_icon

Preventing Hepatitis B Virus Reactivation During Immunochemotherapy for Lymphoma

Administering prophylactic antiviral treatment is effective in preventing hepatitis B virus (HBV) reactivation in patients with B-cell non-Hodgkin lymphoma (NHL) being treated with an...
WIB_icon

Do Children With CVC-Related Thromboses Need Anticoagulation Treatment?

Results from a prospective study of children who were hospitalized in a pediatric intensive care unit (PICU) revealed that the incidence of central vein...
Advertisement

Current Issue

June 2019, Volume 5, Issue 7

This issue features a debate about new treatment options for beta-thalassemia, a look at what’s driving skyrocketing drug prices in myeloma, and more.